MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

HQY

95.46

-0.74%↓

TLRY

1.45

-2.03%↓

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

HQY

95.46

-0.74%↓

TLRY

1.45

-2.03%↓

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

HQY

95.46

-0.74%↓

TLRY

1.45

-2.03%↓

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

HQY

95.46

-0.74%↓

TLRY

1.45

-2.03%↓

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

HQY

95.46

-0.74%↓

TLRY

1.45

-2.03%↓

Search

Puma Biotechnology Inc

Closed

SectorHealthcare

5.22 1.75

Overview

Share price change

24h

Current

Min

5.09

Max

5.25

Key metrics

By Trading Economics

Income

2.9M

5.9M

Sales

6.4M

52M

P/E

Sector Avg

5.505

36.442

Profit margin

11.166

Employees

172

EBITDA

6.8M

11M

Recommendations

By TipRanks

Recommendations

Sell

12 Months Forecast

-44.95% downside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

117M

276M

Previous open

3.47

Previous close

5.22

News Sentiment

By Acuity

50%

50%

153 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 paź 2025, 23:55 UTC

Hot Stocks

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21 paź 2025, 23:49 UTC

Earnings

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21 paź 2025, 21:40 UTC

Earnings

Waste Connections 3Q Revenue Rises

21 paź 2025, 21:14 UTC

Earnings
Major Market Movers

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21 paź 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21 paź 2025, 20:57 UTC

Acquisitions, Mergers, Takeovers

DraftKings to Launch Prediction Markets Platform

21 paź 2025, 20:38 UTC

Earnings

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21 paź 2025, 20:35 UTC

Earnings

Capital One 3Q Sales, Profit Jump

21 paź 2025, 20:32 UTC

Earnings

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21 paź 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 paź 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21 paź 2025, 23:39 UTC

Market Talk

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21 paź 2025, 23:36 UTC

Market Talk

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21 paź 2025, 22:55 UTC

Acquisitions, Mergers, Takeovers

Scentre Says This Forms Part of Capital Management Strategy

21 paź 2025, 22:55 UTC

Acquisitions, Mergers, Takeovers

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21 paź 2025, 22:54 UTC

Acquisitions, Mergers, Takeovers

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21 paź 2025, 21:09 UTC

Market Talk
Earnings

Netflix Creators Have Started Using AI in Production -- Market Talk

21 paź 2025, 20:58 UTC

Market Talk
Earnings

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 paź 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

21 paź 2025, 20:43 UTC

Earnings

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21 paź 2025, 20:41 UTC

Earnings

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21 paź 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21 paź 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21 paź 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21 paź 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21 paź 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21 paź 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21 paź 2025, 20:31 UTC

Acquisitions, Mergers, Takeovers

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21 paź 2025, 20:29 UTC

Earnings

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-44.95% downside

12 Months Forecast

Average 3 USD  -44.95%

High 4 USD

Low 2 USD

Based on 2 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

2 ratings

0

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

153 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat